For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/BRK865. CME/MOC/NCPD/AAPA credit will be available until April 29, 2026.
Exploring the Promise of Biomarkers and ATTs in Diagnosing and Treating Early Symptomatic Alzheimer’s Disease: Key Takeaways From AD/PD 2025 and AAN 2025
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Disclosure information is available at the beginning of the video presentation
View all episodes
By PVI, PeerView Institute for Medical Education
4.1
2525 ratings
For the full presentation, downloadable slides, and complete CME/MOC/NCPD/AAPA information, and to apply for credit, please visit us at PeerView.com/BRK865. CME/MOC/NCPD/AAPA credit will be available until April 29, 2026.
Exploring the Promise of Biomarkers and ATTs in Diagnosing and Treating Early Symptomatic Alzheimer’s Disease: Key Takeaways From AD/PD 2025 and AAN 2025
In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Support
This activity is supported by an educational grant from Lilly.
Disclosure information is available at the beginning of the video presentation
43,543 Listeners
137 Listeners
320 Listeners
698 Listeners
497 Listeners
29 Listeners
11 Listeners
1,384 Listeners
5 Listeners
11 Listeners
3 Listeners
2 Listeners
5 Listeners
2 Listeners
3 Listeners
5 Listeners
5 Listeners
2 Listeners
0 Listeners
9 Listeners
2 Listeners
11 Listeners
2 Listeners
882 Listeners
4 Listeners
3 Listeners
5 Listeners
3,347 Listeners
1,146 Listeners
193 Listeners
92 Listeners
515 Listeners
370 Listeners
426 Listeners